CORTEXYME
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
CORTEXYME
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2012-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.cortexyme.com
Total Employee:
11+
Status:
Active
Total Funding:
225 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Clene Nanomedicine
Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with one approved product.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-05-10 | Novosteo | Novosteo acquired by Cortexyme | N/A |
Investors List
KG Investments
KG Investments investment in Post-IPO Equity - Cortexyme
Smallcap World Fund
Smallcap World Fund investment in Series B - Cortexyme
Vulcan Capital
Vulcan Capital investment in Series B - Cortexyme
Takeda Ventures
Takeda Ventures investment in Series B - Cortexyme
Breakout Ventures
Breakout Ventures investment in Series B - Cortexyme
Huizenga Capital Management
Huizenga Capital Management investment in Series B - Cortexyme
Dolby Family Ventures
Dolby Family Ventures investment in Series B - Cortexyme
EPIQ Capital Group
EPIQ Capital Group investment in Series B - Cortexyme
Lamond Family
Lamond Family investment in Series B - Cortexyme
Verily
Verily investment in Series B - Cortexyme
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-30 | Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate Secretary |
Official Site Inspections
http://www.cortexyme.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
- Host name: s3-website-us-west-1.amazonaws.com
- IP address: 52.219.194.67
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Cortexyme"
Quince Therapeutics - Crunchbase Company Profile & Funding
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. …See details»
Cortexyme - Golden
Cortexyme is a biotechnology company with a focus on developing therapeutics for Alzheimer's disease and other neurodegenerative diseases. It was founded in 2012 and is located in San …See details»
Cortexyme, Inc. - Company Profile & Staff Directory - ContactOut
Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed …See details»
Cortexyme | VentureRadar
Cortexyme is targeting a specific, undisclosed infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The company's lead compound, …See details»
Cortexyme Inc Company Profile - GlobalData
Quince Therapeutics Inc (Quince ), formerly Cortexyme Inc, is a clinical-stage biopharmaceutical company that focused on novel therapeutic approaches to improve the lives of patients …See details»
Cortexyme - businessabc.net
Nov 21, 2024 Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat and slow the progression of serious diseases …See details»
Quince Therapeutics - Craft
Oct 22, 2024 Quince Therapeutics (formerly known as Cortexyme) is a biopharmaceutical company developing therapeutics for Alzheimer's disease and other degenerative disorders. It …See details»
Contacts, Employees, Board Members, Advisors & Alumni
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.See details»
Cortexyme - Company Profile - Tracxn
Nov 27, 2024 Cortexyme. has raised a total funding of $108M over 6 rounds. Its first funding round was on Jun 11, 2014. List of recent funding rounds of Cortexyme. Date of funding. …See details»
Cortexyme, Inc. (CRTX) 10K Annual Reports & 10Q SEC Filings
Mar 1, 2022 incorporation or organization) ... Inside Cortexyme, Inc.'s 10-K Annual Report: Financial - Expense Highlight. We expect our research and development expenses to …See details»
Quince
Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases.See details»
Cortexyme - CoBee Company Profile & Funding Rounds
Cortexyme is a California-based biopharmaceutical company that develops disease-modifying therapeutics for the treatment of neurodegenerative and Alzheimer’s diseases. Contact Phone: …See details»
Cortexyme Company Profile: Overview and Full News Analysis
Cortexyme is a biopharmaceutical company based in California that focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. The company is …See details»
Cortexyme Raises $15 Million Series A - Pfizer
Jan 6, 2016 Cortexyme previously raised $1.025 million including an investment award from Breakout Labs. ABOUT CORTEXYME Cortexyme is a private company based in South San …See details»
Cortexyme (USA) Funding: $225M - Medical Startups
Jun 11, 2019 Cortexyme is developing novel treatments for altering the course of Alzheimer's and other degenerative...See details»
Cortexyme | CRTX Stock Price, Company Overview & News - Forbes
Why Has Cortexyme’s Stock Jumped 2.5x So Far This Month Cortexyme (NASDAQ: CRTX) is a clinical stage bio-pharmaceutical company working on Alzheimer’s and other degenerative …See details»
Cortexyme Announces Change in Executive Leadership Team
Feb 1, 2022 Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients …See details»
Cortexyme Completes $76 Million Series B Financing and ... - Pfizer
May 31, 2018 – Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388 – SOUTH SAN FRANCISCO, Calif.- …See details»
Cortexyme Presents Updated Baseline Data from Complete Set of ...
Jun 1, 2021 Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients …See details»